RESUMEN
Ghrelin, an orexigenic hormone of gastric origin that stimulates growth hormone secretion, may modulate inflammation. This experimental study examines the effect of ghrelin on NFκB (p65 subunit), a transcriptional factor involved in inflammation on a human B-lymphocyte cell (WILCL). After confirming the expression of ghrelin receptor protein using western blotting the cells were transferred to wells maintaining a density of 1 × 10(6) cells per ml and a proportion activated with phytohaemagluttinin. Activated and resting cells were exposed to octanoyl-, desoctanoyl ghrelin and a non-peptide ghrelin agonist (Pfizer CP-464709) in increasing concentrations for 6 h. Cell protein extracts were analyzed for NFκB activation using Trans AM NFκB p65 assay. IL-6, IL-8, IL-10, IL-13 and TNFα were measured in the media using Lincoplex human cytokine assay. In octanoyl ghrelin treated resting cells, NFκB activity (Optical Density OD(450 nm)) (mean ± SEM) in control cells was 0.42 ± 0.10 and increased to 0.61 ± 0.20 (P = 0.044), 0.54 ± 0.10 (P = 0.043), 0.52 ± 0.08 at 1, 10 and 100 nM concentrations respectively. No effect was detected with desoctanoyl ghrelin or ghrelin agonist and no specific change in cytokine production. In conclusion, Octanoyl ghrelin increased NFκB activation by up to 50% in a B-lymphocyte cell line suggesting an effect on the inflammatory process.
Asunto(s)
Linfocitos B/efectos de los fármacos , Linfocitos B/metabolismo , Ghrelina/farmacología , FN-kappa B/metabolismo , Western Blotting , Línea Celular , Medios de Cultivo/farmacología , Citocinas/metabolismo , Humanos , Activación de Linfocitos/efectos de los fármacos , Receptores de Ghrelina/agonistas , Receptores de Ghrelina/metabolismoRESUMEN
CONTEXT: Visceral adipose tissue (AT) is known to confer a significantly higher risk of type 2 diabetes and cardiovascular disease. Epicardial AT has been shown to be related to cardiovascular disease and myocardial function through unidentified mechanisms. Epicardial AT expresses an inflammatory profile of proteins; however, the mechanisms responsible are yet to be elucidated. OBJECTIVES: The objectives of the study were to: 1) examine key mediators of the nuclear factor-kappaB (NFkappaB) and c-Jun N-terminal kinase (JNK) pathways in paired epicardial and gluteofemoral (thigh) AT from coronary artery disease (CAD) and control patients and 2) investigate circulating endotoxin levels in CAD and control subjects. DESIGN: Serums and AT biopsies (epicardial and thigh) were obtained from CAD (n = 16) and non-CAD (n = 18) patients. Inflammation was assessed in tissue and serum samples through Western blot, real-time PCR, ELISAs, and activity studies. RESULTS: Western blotting showed epicardial AT had significantly higher NFkappaB, inhibitory-kappaB kinase (IKK)-gamma, IKKbeta, and JNK-1 and -2 compared with thigh AT. Epicardial mRNA data showed strong correlations between CD-68 and toll-like receptor-2, toll-like receptor-4, and TNF-alpha. Circulating endotoxin was elevated in patients with CAD compared with matched controls [CAD: 6.80 +/- 0.28 endotoxin unit(EU)/ml vs. controls: 5.52 +/- 0.57 EU/ml; P<0.05]. CONCLUSION: Epicardial AT from patients with CAD shows increased NFkappaB, IKKbeta, and JNK expression compared with both CAD thigh AT and non-CAD epicardial AT, suggesting a depot-specific as well as a disease-linked response to inflammation. These studies implicate both NFkappaB and JNK pathways in the inflammatory profile of epicardial AT and highlight the role of the macrophage in the inflammation within this tissue.
Asunto(s)
Tejido Adiposo/fisiología , Enfermedad de la Arteria Coronaria/complicaciones , Inflamación/etiología , Proteínas Quinasas JNK Activadas por Mitógenos/fisiología , FN-kappa B/fisiología , Pericardio/metabolismo , Anciano , Antígenos CD/genética , Antígenos de Diferenciación Mielomonocítica/genética , Endotoxinas/sangre , Femenino , Humanos , Proteínas Quinasas JNK Activadas por Mitógenos/análisis , Masculino , Persona de Mediana Edad , FN-kappa B/análisis , Fosforilación , ARN Mensajero/análisis , Receptor Toll-Like 4/genética , Factor de Necrosis Tumoral alfa/genéticaRESUMEN
BACKGROUND: Ghrelin, a potent orexigenic peptide produced by the stomach, may be affected by circulating inflammatory mediators. AIM: To assess the effect of an anti-TNFα antibody on ghrelin in patients with Crohn's disease (CD). METHODS: Fifteen patients with Crohn's receiving infliximab were studied before and 1 week after infusion. Following an overnight fast, blood was sampled before a meal and then every 20 min for 2 h. Total ghrelin and CRP were measured using ELISA. Acylated ghrelin and TNFα, IFNγ, IL-1ß and IL-6 were measured with bioplex. Harvey Bradshaw Activity Index was assessed. RESULTS: Median (95% CI) 2-h integrated plasma total ghrelin increased from 162 (99-311) before infliximab to 200 (128-387) pg/mL h, (P = 0.02) after. Following infliximab, 20 min postmeal, median acylated ghrelin decreased from 50.3 (24-64) to 38.6 (26-82) pg/mL, (P = 0.04) thus reverting to a traditional meal related ghrelin curve. Median (range) disease activity decreased from 5 (2-28) before to 3 (0-22), (P = 0.0001) and Median (95% CI) TNFα decreased from 2.8 (1.89-4.48) to 1.31 (0.73-2.06) pg/mL (P = 0.002). CONCLUSIONS: Infliximab increases circulating total ghrelin by 25% in CD and restores the postprandial response of acylated ghrelin to food intake. Acylated and de-sacyl ghrelin remain unchanged, suggesting that an alternate isoform could be affected by infliximab.
Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Enfermedad de Crohn/tratamiento farmacológico , Fármacos Gastrointestinales/uso terapéutico , Ghrelina/sangre , Mediadores de Inflamación/uso terapéutico , Factor de Necrosis Tumoral alfa/uso terapéutico , Adulto , Anticuerpos Monoclonales/sangre , Enfermedad de Crohn/sangre , Ensayo de Inmunoadsorción Enzimática , Femenino , Fármacos Gastrointestinales/sangre , Humanos , Mediadores de Inflamación/sangre , Infliximab , Masculino , Persona de Mediana Edad , Factor de Necrosis Tumoral alfa/sangre , Adulto JovenRESUMEN
UNLABELLED: Type 2 diabetes (T2DM) is associated with chronic low-grade inflammation. Adipose tissue (AT) may represent an important site of inflammation. 3T3-L1 studies have demonstrated that lipopolysaccharide (LPS) activates toll-like receptors (TLRs) to cause inflammation. For this study, we 1) examined activation of TLRs and adipocytokines by LPS in human abdominal subcutaneous (AbdSc) adipocytes, 2) examined blockade of NF-kappaB in human AbdSc adipocytes, 3) examined the innate immune pathway in AbdSc AT from lean, obese, and T2DM subjects, and 4) examined the association of circulating LPS in T2DM subjects. The findings showed that LPS increased TLR-2 protein expression twofold (P<0.05). Treatment of AbdSc adipocytes with LPS caused a significant increase in TNF-alpha and IL-6 secretion (IL-6, CONTROL: 2.7+/-0.5 vs. LPS: 4.8+/-0.3 ng/ml; P<0.001; TNF-alpha, CONTROL: 1.0+/-0.83 vs. LPS: 32.8+/-6.23 pg/ml; P<0.001). NF-kappaB inhibitor reduced IL-6 in AbdSc adipocytes ( CONTROL: 2.7+/-0.5 vs. NF-kappaB inhibitor: 2.1+/-0.4 ng/ml; P<0.001). AbdSc AT protein expression for TLR-2, MyD88, TRAF6, and NF-kappaB was increased in T2DM patients (P<0.05), and TLR-2, TRAF-6, and NF-kappaB were increased in LPS-treated adipocytes (P<0.05). Circulating LPS was 76% higher in T2DM subjects compared with matched controls. LPS correlated with insulin in controls (r=0.678, P<0.0001). Rosiglitazone (RSG) significantly reduced both fasting serum insulin levels (reduced by 51%, P=0.0395) and serum LPS (reduced by 35%, P=0.0139) in a subgroup of previously untreated T2DM patients. In summary, our results suggest that T2DM is associated with increased endotoxemia, with AT able to initiate an innate immune response. Thus, increased adiposity may increase proinflammatory cytokines and therefore contribute to the pathogenic risk of T2DM.
Asunto(s)
Diabetes Mellitus Tipo 2/inmunología , Inmunidad Innata/efectos de los fármacos , Lipopolisacáridos/farmacología , Obesidad/inmunología , Grasa Subcutánea Abdominal/efectos de los fármacos , Adipocitos Blancos/efectos de los fármacos , Adipocitos Blancos/inmunología , Adipocitos Blancos/metabolismo , Adulto , Anciano , Células Cultivadas , Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/patología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Factor 88 de Diferenciación Mieloide/metabolismo , FN-kappa B/antagonistas & inhibidores , Obesidad/sangre , Obesidad/patología , Grasa Subcutánea Abdominal/inmunología , Grasa Subcutánea Abdominal/metabolismo , Factor 6 Asociado a Receptor de TNF/metabolismo , Receptores Toll-Like/metabolismoRESUMEN
The 3p21.3 RASSF1A tumour suppressor gene (TSG) provides a paradigm for TSGs inactivated by promoter methylation rather than somatic mutations. Recently, we identified frequent promoter methylation without somatic mutations of SLIT2 in lung and breast cancers, suggesting similarities between SLIT2 and RASSF1A TSGs. Epigenetic inactivation of RASSF1A was first described in lung and breast cancers and subsequently in a wide range of human cancers including neuroblastoma, Wilms' tumour and renal cell carcinoma (RCC). These findings prompted us to investigate SLIT2 methylation in these three human cancers. We analysed 49 neuroblastomas (NBs), 37 Wilms' tumours and 48 RCC, and detected SLIT2 promoter methylation in 29% of NB, 38% of Wilms' tumours and 25% of RCC. Previously, we had demonstrated frequent RASSF1A methylation in the same tumour series and frequent CASP8 methylation in the NB and Wilms' tumour samples. However, there was no significant association between SLIT2 promoter methylation and RASSF1A or CASP8 methylation in NB and RCC. In Wilms' tumour, there was a trend for a negative association between RASSF1A and SLIT2 methylation, although this did not reach statistical significance. No associations were detected between SLIT2 promoter methylation and specific clinicopathological features in the tumours analysed. These findings implicate SLIT2 promoter methylation in the pathogenesis of both paediatric and adult cancers and suggest that further investigations of SLIT2 in other tumour types should be pursued. However, epigenetic inactivation of SLIT2 is less frequent than RASSF1A in the tumour types analysed.
Asunto(s)
Carcinoma de Células Renales/genética , Metilación de ADN , Neoplasias Renales/genética , Proteínas del Tejido Nervioso/genética , Neuroblastoma/genética , Regiones Promotoras Genéticas , Tumor de Wilms/genética , Adulto , Edad de Inicio , Carcinoma de Células Renales/fisiopatología , Niño , ADN de Neoplasias/genética , Epigénesis Genética , Humanos , Péptidos y Proteínas de Señalización Intercelular , Neoplasias Renales/fisiopatología , Neuroblastoma/fisiopatología , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Tumor de Wilms/fisiopatologíaRESUMEN
The objective of the present study was to determine whether there is a synergistic effect of malnutrition and ethanol exposure on neuromotor development. Ethanol (E) (6 g/kg) or sucrose (S) (isocaloric to ethanol) was administered by gavage to ad libitum-fed (A) and malnourished (M) pregnant rats on days 18, 19 and 20 of pregnancy. Malnutrition was produced by food restriction to 50% of control intake. At birth, the offspring were weighed and transferred to surrogate mothers. Performance in the rim-escape test and on the rotating rod were evaluated on days 19 and 28 of life, respectively. Development of the adult swimming pattern was also studied. The results indicated that: 1) malnutrition alone decreased birth weight (g) significantly (AE, 5.56 +/- 0.36; AS, 6.31 +/- 1.05; ME, 4.81 +/- 0.73; MS, 5.23 +/- 0.57); 2) a synergistic interaction between alcohol exposure and malnutrition was observed only in the rim escape test (percent of falling rats: AE, 9; AS, 5; ME, 24; MS, 5); 3) only malnutrition retarded development of swimming; 4) malnourished dams gained more weight (g) than controls during treatment with ethanol (AE, 2.6 +/- 8.4, N = 6; AS, 3.1 +/- 8.4, N = 4; ME, 23.0 +/- 6.3, N = 7; MS, 29.0 +/- 9.0, N = 8). These results indicate a possible synergistic action between malnutrition and ethanol on neuromotor development and point to the importance of ethanol as a calorie source for malnourished animals.
Asunto(s)
Etanol/farmacología , Actividad Motora/efectos de los fármacos , Desnutrición Proteico-Calórica/fisiopatología , Desempeño Psicomotor/efectos de los fármacos , Análisis de Varianza , Animales , Peso Corporal , Dieta , Etanol/administración & dosificación , Femenino , Embarazo , Ratas , Factores de TiempoRESUMEN
The objective of the present study was to determine whether there is a synergistic effect of malnutrition and ethanol exposure on neuromotor development. Ethanol (E) (6 g/kg) or sucrose (S) (isocaloric to ethanol) was administered by gavage to ad libitum-fed (A) and malnourished (M) pregnant rats on days 18, 19 and 20 of pregnancy. Malnutrition was produced by food restriction to 50 of control intake. At birth, the offspring were weighed and transferred to surrogate mothers. Performance in the rim-escape test and on the rotating rod were evaluated on days 19 and 28 of life, respectively. Development of the adult swimming pattern was also studied. The results indicated that: 1) malnutrition alone decreased birth weight (g) significantly (AE, 5.56 +/- 0.36; AS, 6.31 +/- 1.05; ME, 4.81 +/- 0.73; MS, 5.23 +/- 0.57); 2) a synergistic interaction between alcohol exposure and malnutrition was observed only in the rim escape test (percent of falling rats: AE, 9; AS, 5; ME, 24; MS, 5); 3) only malnutrition retarded development of swimming; 4) malnourished dams gained more weight (g) than controls during treatment with ethanol (AE, 2.6 +/- 8.4, N = 6; AS, 3.1 +/- 8.4, N = 4; ME, 23.0 +/- 6.3, N = 7; MS, 29.0 +/- 9.0, N = 8). These results indicate a possible synergistic action between malnutrition and ethanol on neuromotor development and point to the importance of ethanol as a calorie source for malnourished animals.